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Erythema induratum (EI), also known as nodular vasculitis and erythema induratum 
of Bazin, is a chronic nodular eruption often found on the posterior aspect of the 
lower legs in middle aged females. (1) It is a reactive disorder to mycobacterium 
tuberculosis (MTB) infection although other etiological entities also exist.  (2) Because 
MTB cannot be cultured within individual lesions the relationship between EI and 
MTB has been questioned. (3) Some literature suggests that the term “nodular 
vasculitis of Bazin” should be reserved for the portion of nodular vasculitis caused by 
MTB. (4) 
 
Cutaneous TB can present with a variety of clinical manifestations but remains a rare 
form of extrapulmonary TB.  EI is considered a type of cutaneous TB.  Cutaneous 
tuberculosis can be divided into the route of infection: inoculated MTB from an 
exogenous source, from a systemic primary focus or as a tuberculid.(5) Erythema 
induratum is regarded as a tuberculid and therefore meant to fulfil the criteria: a 
positive tuberculin test, MTB involvement of the lymph nodes or internal viscera, a 
negative culture of the skin biopsy and resolution on antituberculosis treatment. (6) 
Another tuberculid has been suggested, nodular tuberculid, where changes similar to 
EI and papulonecrotic tuberculid occur within the lower dermis. (7) 
 
Table 1) Types of cutaneous TB 
Exogenous cutaneous TB Tuberculosis chancre 
Tuberculosis verrucose cutis 





Acute milliary tuberculosis 






The exact epidemiology of cutaneous TB is not known. A large multicenter 
observational study of 202998 patients with extrapulmonary TB from China gave an 
incidence of 0.42% of cutaneous TB. (8) Of 636 cases of extrapulmonary TB in 
Turkey, 1.9% had cutaneous TB. (9) Other authors have found higher incidences of 
cutaneous TB in all clinical cases of TB, these ranged between 2.4 and 4.8%. (10-13) A 
South African study reported on cutaneous conditions in patients admitted to a TB 
hospital, three of 105 patients had cutaneous TB, none of them were EI. (14) 
 
Few reports on the subset who has EI, a study by Spelta et al reviewed all the cases 
of cutaneous TB in a state of Brazil with a high incidence of TB, over 26 years they 
had an incidence of only 0.44% of cutaneous TB.  Of these EI was the most common 
presentation at 41.4% of all cutaneous TB cases. (15) Overall cutaneous TB remains 
a small percentage of all clinical presentations of TB. 
 
The diagnosis of EI is more commonly based on clinical and histological findings. 
Although non-ulcerated lesions may heal without scarring, often subcutaneous 
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nodules become adherent to the skin surface and ulcerate. Lesions are usually 
tender but may be indolent or painful only on pressure.  The course is prolonged and 
recurrent episodes over years are common. Individual lesions tend to involute, but 
new crops appear at irregular intervals. (1) Histologically it is the most common form 
of lobular panniculitis with vasculitis, although many controversies exist on the nature 
and percentage of vessel involvement.  
 
Fig. 1a Fig. 1b 
Fig. 1c Fig. 1d 
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Fig 1. a-f) Clinical features of EI 
Above pictures are all examples of clinicopathologically confirmed cases of EI.  This 
illustrates the broad spectrum of clinical presentations:   
Fig. 1a) Erythematous to violaceous subcutaneous nodules, note the areas of 
peripheral scale and adherence to the surface in the centre of the lesion, a sign 
of impending ulceration. 
Fig. 1b) More subtle hyperpigmented to violaceous subcutaneous nodules 
presenting on the calves. 
Fig 1c) Erythematous to violaceous nodules that ulcerate onto the surface. 
Fig. 1d) Violaceous nodules predominantly on the inner calves, some showing 
impending central ulceration. 
Fig. 1e) Violaceous subcutaneous nodules on the calves ulcerating onto the 
surface. 
Fig 1. f) Hyperpigmentation on the upper part of the lower leg showing older 
healed pathology.  Lower down on the shin showing ulceration. 





We conduct this literature search with the aim to peruse available literature on this 
rare condition, placing special emphasis on what is already available and 
controversies that exist. 
 
All publications relevant to the subject were obtained via the University of Cape 
Town Health Sciences library.  For the purposes of this study the most recent search 
was conducted in November 2020 using the Pubmed database and the following 
search terms: “erythema induratum” or “nodular vasculitis” or “erythema induratum of 
Bazin”.  Articles were excluded if they were not relevant to the subject.  Literature not 
published in the English language was excluded. Due to the rarity of the condition no 




Relationship between MTB and EI 
 
 
The pathogenesis of EI has been described as a type 3 hypersensitivity reaction due 
to the immune complex mediated vasculitis detected on histological examination. A 
type 4 hypersensitivity reaction has also been implicated due to the presence of T 
lymphocyte mediated response. MTB being the most common antigen responsible 
for the hypersensitivity reaction.  (16) These mechanisms are clinically apparent in the 
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exaggerated response to purified protein derivative (PPD in the Mantoux intradermal 
test) in patients with erythema induratum. An interferon gamma release assay 
(IGRA) would also be a sensitive alternative in detecting the presence of MTB in 
erythema induratum. (17) Both of these investigations pose diagnostic difficulties in 
our setting where there will be a high false negative rate due to immunosuppressed 
patients with false negative Mantoux, also high incidence of Bacille Calmette-Guérin 
(BCG) immunisations leads to difficulties in interpretation of the Mantoux result.   Our 
high incidence of latent tuberculosis shows a high false positive result in the IGRA. 
(18) 
 
Because (MTB) cannot be cultured in the lesion the etiological relation to erythema 
induratum remains controversial. However, in recent years numerous studies 
reported the presence of MTB DNA by polymerase chain reaction (PCR). These 
results include positive MTB DNA detection by PCR in 77% of 65 patients, 75% of 12 
patients, 14% of 65 patients and 25% of 20 patients with erythema induratum. (19-23) 
Although erythema induratum has been associated with other entities the association 
with tuberculosis remains most important in our setting where there is a high 
incidence of tuberculosis.  
 
 
Histological features and controversies  
 
From a histologic point of view, EI is mostly a lobular panniculitis. Initially an 
inflammatory infiltrate, mostly neutrophils collect in the fat lobules. There may be 
extensive necrosis of the adipocytes of the fat lobule and foamy histiocytes may 
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appear. Epithelioid histiocytes, multinucleated giant cells, and lymphocytes 
contribute to the granulomatous appearance of the inflammatory infiltrate in fully 
developed lesions. When intense vascular damage is present, extensive areas of 
caseous necrosis appear and the lesions show all the histopathologic attributes of 
tuberculosis. Caseous necrosis may extend to the overlying dermis and secondarily 
involve the epidermis with ulceration and discharge of liquefied necrotic fat. (1) 
 
 
Fig 2. a-c). Histological features of EI  
Above pictures demonstrate a lobular panniculitis.  
Fig. 2 a) Caseous necrosis with neutrophilic infiltrate, where it is evident that 
the fat cells are of different sizes and there is a dense inflammatory infiltrate 
causing caseous necrosis.   
Fig. 2 b) Lobular necrosis, where it there are anucleate adipocytes of different 
diameter. 
Fig 2a Fig 2b 
Fig 2c 
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Fig. 2 c) High power view of inflammation of the vessel. 
 
Controversy persists in the literature about the nature of the vessel involved. 
Schneider et al reviewed 19 cases where 6 had vasculitis of muscular arteries and 
small vessels and 6 had vasculitis of small and large vessels. (16) Segura et al 
demonstrated vasculitis in 90% of their 86 patients, mostly affecting small venules in 
the lobules, followed by venules in the septal area surrounding the fat lobules, 
venules in both septa and lobules and finally involvement of arteries.  (24) Standard 
textbooks also differ in their description of the vessel involved. Rapini et al suggests 
vasculitis involving the arteries and small veins, (25) Weedon et al reports any size 
vessel being involved. (26) Elston et al suggests a neutrophilic vasculitis of the septum 
is often present. (27) These variations in histological features make EI a difficult and 
often confusing diagnosis. Whether the vasculitis is septal or lobular and the exact 
nature of the vessels is yet to be determined. 
 
Granuloma formation within the histology sections seems to be a predominating 
feature.  It is also well known that the predominate focus of inflammation withing the 
panniculus is lobular or septolobular.  In contrast to this erythema nodosum tends to 
be predominately a septal panniculitis.  Schneider et al divided their investigated 
cases into two groups. Both groups were described as septolobular panniculitides 
that showed varying combinations and degrees of acute and chronic inflammation, 
coagulative and caseation-like necrosis, and granulomatous inflammation. Poorly 
developed granulomas predominated, but mixed, palisading, and lipophagic 
granulomas also occurred.  Schneider concludes that EI remains a clinicopathologic 
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diagnosis, but awareness of the heterogeneous histopathologic spectrum of EI will 
ensure a timely diagnosis and institution of antituberculous treatment. (16) 
  
 
Erythema nodosum as controls 
 
Erythema nodosum (EN) was used in our study as the comparative condition. 
Because we aim to let a group of dermatologists assess the features of EI blinded 
we included EN cases into the study. Although known as the lower leg panniculitides 
sharing similar clinical and histological features, EN and EI are distinctive pathologic 
entities.  EN is the most common form of panniculitis and described as commonly 
occurring on the shins as opposed to EI that is described as occurring on the calves. 
In practice these conditions act as the main differential diagnoses for each other and 
are not always easy to distinguish. Therefore, a biopsy is often performed and with 
the added information the diagnosis becomes more apparent.  As mentioned EI is 
predominantly a lobular panniculitis, whereas in EN the focus of inflammation occurs 
primarily within the septum of the panniculus.  Where MTB is often the triggering 
factor for EI, EN on the other hand has many identified potential triggers including 
infectious agents, medications and underlying systemic disorders.  Rarely MTB can 
be a triggering factor in EN, but more often streptococcal throat infection or 




Fig. 3 a-d) Clinical features of EN 
Above four different patients with clinicopathologically confirmed EN can be 
witnessed.   
Fig 3a Fig 3b 
Fig 3c Fig 3d 
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Fig. 3 a) Erythematous to hyperpigmented subcutaneous nodules can be 
seen on the calves. 
Fig. 3 b) Erythematous nodule over the shin 
Fig. 3 c) Violaceous nodules predominantly on the shins 




 Fig. 4 a-b) Histological features of EN 
Fig. 4 a) A septal panniculitis where the focus of inflammation is 
predominantly within the septum causing widening of the septum. 
Fig. 4 b) Although there might be inflammation within the lobular component, 
the focus of inflammation remains within the septum.  Granulomas might be 
found within the septum. 
 
A deep biopsy to classify the type of panniculitis is often performed. Although 
trephine punches have been proposed for biopsies of panniculitides, an incisional 
biopsy with a larger scalpel that extends through the subcutaneous fat is preferred.  
(29) This might lead to unfavorable wound healing especially if the section is taken 
from the lower leg.  It is for this reason that some clinicians aim to not take a biopsy 
Fig 4a Fig 4b 
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for cases of EN, believing that there are no harmful underlying conditions to exclude 
and that the condition is generally self-limiting. It is therefore important to study the 
clinical features of EN and EI and see if these entities can be distinguished based 
only on clinical examination.   
 
 
Gaps in the literature  
 
The literature available on erythema induratum is lacking. Small cohorts are 
available due to the rarity of the disease and the exact incidence is not known. A 
previous study done in South Korea identified 53 patients prospectively and in Brazil 
54 cases retrospectively.  (30, 31) In Spain 86 cases were collected retrospectively at 2 
institutions and 65 cases at one institution over an undefined period of time. (20, 22, 24) 
These make out the largest cohorts. Numerous smaller studies and case reports 
also report on erythema induratum.  Few studies correlate the clinical and 
histological features of this condition. 
 
A study done by Rademaker et al, reviewed clinical and histologic features of 26 
cases of EI. The characteristic cutaneous lesions on the legs of middle-aged women 
were violaceous, indurated nodules, 1 to 2 cm in diameter, which were painful, 
occasionally ulcerated, and could heal with scarring. The histologic features were 
varied but were predominantly those of a vasculitis with a septolobular and lobular 
panniculitis. (32) These cases were confirmed by having a strongly positive Mantoux 
test. This is not feasible in our setting where there is a high incidence of latent TB 
and a high incidence of HIV, making the interpretation of the result difficult. 
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Previous South African studies (16, 23) focused predominantly on the histological 
features and did not correlate them with the clinical features in their description.  
Considering the high prevalence of TB in South Africa more local studies are needed 
to describe this cutaneous manifestation of MTB.  This is particularly important when 
considering the diagnosis of TB since EI can be the presenting feature of underlying 
TB where there is strong enough immunity to suppress other clinical symptoms of TB 
for example marked chest X-ray changes and systemic symptoms. 
 
Once the diagnosis of EI is confirmed a systemic source of TB should be 
investigated.  There is no clear mention in the literature of what investigations should 
be performed nor whether EI is associated with pulmonary or extrapulmonary TB. 
Patients who develop hypersensitivity reactions in EI generally have good cellular 
immunity, and the source of TB infection can be difficult to detect.  Few case reports 
mention extrapulmonary TB related to the clinical diagnosis of EI. Examples include 
hepatic TB, renal tuberculosis and endometrial TB. (33-35) 
These case reports are likely an overrepresentation and pulmonary TB is 
underrepresented because it is the most common presentation of TB.  There is 
however mention that childhood cutaneous TB represents 18% to 82% of all 
cutaneous tuberculosis cases. Scrofuloderma and lupus vulgaris (both cutaneous 
presentations of TB) are the two most common clinical forms in children. An increase 
in the number of tuberculids, especially lichen scrofulosorum, has been observed in 




There is little mention of specific management of EI in the literature.  As for the 
management of EN an underlying precipitant should be treated, in the case of EI this 
is most often systemic antituberculosis therapy to treat MTB infection.  Thereafter 
non-steroidal anti-inflammatories plus rest and elevation of the legs constitute the 
mainstay of treatment.  For resistant cases colchicine and potassium iodide are 
instituted.(28)  A single case report mentions topical isoniazid as specific treatment for 
EI. (37) 
 
After extensive review of the literature it is evident that EI is a rare presentation of a 
hypersensitivity reaction to TB that is under reported in the literature.  Available 
research highlights the difficulties in making an accurate diagnosis. There is 
conflicting evidence for the clinical and histological features of EI.  Also Mantoux and 
IGRA testing pose interpretation difficulties in our South African setting.   
 
Although these clinical and histological guidelines are given in most texts, practically 
it remains a difficult clinical and histological diagnosis. EI is also a rare condition 
making large prospective studies with conclusive results difficult.  Using EN as an 
alternative clinical condition we will test a group of dermatologists on their ability to 
distinguish EI and EN.  This will be based first on the clinical images and then the 
histological features will be revealed.  The ability of the initial assessment and the 
contributing value of the histological features will be assessed.  We aim to 
investigate what clinical and histological features contribute most to an accurate 
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Background - Erythema induratum (EI) is a reactive disorder to mycobacterium 
tuberculosis infection, a diagnosis not to be missed.  Erythema nodosum (EN) is the 
main clinical differential of EI, but a distinctly different pathological condition that can 
be difficult to distinguish from EI. 
Methods – In this retrospective review we assess clinical and histological features of 
40 EI cases and 16 EN cases.  Six experienced dermatologists blindly diagnosed 
these cases based on clinical images, thereafter the histology was revealed, and 
they adjusted their diagnoses accordingly.  Fleiss Kappa statistics were applied to 
determine inter-rater variability.  A multi-variate logistic regression model determined 
the clinical and histological features that contribute most to an accurate diagnosis. 
Results - After assessing the clinical picture 48.8% of the EI cases and 74% of the 
EN cases were correctly diagnosed.  With added histology results 67.1% EI and 
81.2% EN cases were correct.  EI cases showed inter-rater variability of 0.478 (p-
value < 0.01) before and 0.469 (p-value < 0.01) after histology was revealed. These 
features combined in a logistic regression model had a higher diagnostic accuracy 
than the assessors with regard to EI cases.  The model was accurate in 100% and 
80% of EI and EN cases respectively. 
Conclusions - While the study was limited by its retrospective nature and small 
sample size, valuable features (ulceration, vasculitis and lobular or septal 
panniculitis) were identified.    A biopsy of the lower leg markedly increased the 
diagnostic accuracy, but there was less concordance between assessors, more 









Erythema induratum (EI), also known as nodular vasculitis and erythema induratum 
of Bazin, is a chronic nodular eruption often found on the posterior aspect of the 
lower legs in middle aged females. (1) It is a reactive disorder to mycobacterium 
tuberculosis (MTB) infection although other etiological entities also exist.  (2) EI is 
regarded as a tuberculid and therefore should fulfil the criteria: a positive tuberculin 
test, mycobacterium tuberculosis involvement of the lymph nodes or internal viscera, 
a negative culture of the skin biopsy and resolution on antituberculosis treatment. (3) 
Because MTB cannot be cultured within individual lesions the relationship between 
EI and MTB has been questioned. (4) Some literature suggests that the term “nodular 
vasculitis of Bazin” should be reserved for the portion of nodular vasculitis caused by 
MTB. (5) 
 
Clinically EI presents as subcutaneous nodules on the calves. Although non-
ulcerated lesions may heal without scarring, often subcutaneous nodules become 
adherent to the skin surface and ulcerate. Lesions are usually tender but may be 
indolent or painful only on pressure.  The course is prolonged and recurrent 
episodes over years are common. Individual lesions tend to involute, but new crops 
appear at irregular intervals. (1) Histologically it is the most common form of lobular 
panniculitis with vasculitis, although many controversies exist on the nature of the 
vessel involved and percentage who has vessel involvement. 
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The pathogenesis of EI has been described as a type 3 hypersensitivity reaction due 
to the immune complex mediated vasculitis detected on histological examination. A 
type 4 hypersensitivity reaction has also been implicated due to the presence of T 
lymphocyte mediated response. MTB being the most common antigen responsible 
for the hypersensitivity reaction. (6) These mechanisms are clinically apparent in the 
exaggerated response to purified protein derivative (PPD in the Mantoux intradermal 
test) in patients with EI. An interferon gamma release assay would also be a 
sensitive alternative in detecting the presence of MTB in EI. (7) Both of these 
investigations pose diagnostic difficulties in the South African setting where there will 
be a high false negative rate due to immunosuppressed patients with false negative 
Mantoux, also high incidence of bacille Calmette-Guérin (BCG) immunisations leads 
to difficulties in interpretation of the Mantoux result.   Our high incidence of latent 
tuberculosis shows a high false positive result in the interferon-gamma release 
assay. (8) 
 
From a histologic point of view, EI is mostly a lobular panniculitis. Initially an 
inflammatory infiltrate, mostly neutrophils collect in the fat lobules. There may be 
extensive necrosis of the adipocytes of the fat lobule and foamy histiocytes may 
appear. Epithelioid histiocytes, multinucleated giant cells, and lymphocytes 
contribute to the granulomatous appearance of the inflammatory infiltrate in fully 
developed lesions. When intense vascular damage is present, extensive areas of 
caseous necrosis appear and the lesions show all the histopathologic attributes of 
tuberculosis. Caseous necrosis may extend to the overlying dermis and secondarily 
involve the epidermis with ulceration and discharge of liquefied necrotic fat. (1) 
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Controversy persists in the literature about the nature of the vessel involved. 
Schneider et al reviewed 19 cases where 6 had vasculitis of muscular arteries and 
small vessels and 6 had vasculitis of small and large vessels. (6) Segura et al 
demonstrated vasculitis in 90% of their 86 patients, mostly affecting small venules in 
the lobules, followed by venules in the septal area surrounding the fat lobules, 
venules in both septa and lobules and finally involvement of arteries. (9) Standard 
textbooks also differ in their description of the vessel involved. Rapini et al suggests 
vasculitis involving arteries and small veins, (10) Weedon et al reports any size vessel 
being involved.  (11) Elston et al suggests a neutrophilic vasculitis of the septum is 
often present.(12) These variations in histological features make EI a difficult and 
often confusing diagnosis. Whether the vasculitis is septal or lobular and the exact 
nature of the vessels is yet to be determined. 
 
Granuloma formation within the histology sections seems to be a predominating 
feature.  It is also well known that the predominant focus of inflammation withing the 
panniculus is lobular or septolobular.  In contrast to this EN tends to be 
predominantly a septal panniculitis.  Schneider et al divided their investigated cases 
into two groups. Both groups were described as septolobular panniculitides that 
showed varying combinations and degrees of acute and chronic inflammation, 
coagulative and caseation-like necrosis, and granulomatous inflammation. Poorly 
developed granulomas predominated, but mixed, palisading, and lipophagic 
granulomas also occurred.  Schneider concludes that EI remains a clinicopathologic 
diagnosis, but awareness of the heterogeneous histopathologic spectrum of EI will 
ensure a timely diagnosis and institution of antituberculous treatment.(6) 
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Erythema nodosum (EN) was used in our study as the comparative condition. 
Because we aimed to let a group of dermatologists assess the features of EI blinded, 
we included EN cases in the study. Although known as the lower leg panniculitides 
sharing similar clinical and histological features, EN and EI are distinctive pathologic 
entities.  EN is the most common form of panniculitis and described as commonly 
occurring on the shins as opposed to EI that is described as occurring on the calves. 
In practice these conditions act as the main differential diagnoses for each other and 
are not always easy to distinguish. Therefore, a biopsy is often performed and with 
the added information the diagnosis becomes more apparent.  As mentioned EI is 
predominantly a lobular panniculitis, whereas in EN the focus of inflammation occurs 
primarily within the septum of the panniculus.  Where MTB is often the triggering 
factor for EI, EN on the other hand has many identified potential triggers including 
infectious agents, medications and underlying systemic disorders.  Rarely MTB can 
be a triggering factor in EN, but more often streptococcal throat infection or 
gastrointestinal infections are the causative organisms. (13) 
 
A deep biopsy to classify the type of panniculitis is often performed. Although 
trephine punches have been proposed for biopsies of panniculitides, an incisional 
biopsy with a larger scalpel that extends through the subcutaneous fat is preferred. 
(14) This might lead to unfavorable wound healing especially if the section is taken 
from the lower leg.  It is for this reason that some clinicians aim to not take a biopsy 
for cases of EN, believing that there are no harmful underlying conditions to exclude 
and that the condition is generally self-limiting. Therefore, we aim to study the clinical 
features of EN and EI and see if these entities can be distinguished based only on 
clinical examination and what contributing value a biopsy adds. 
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Materials and Methods 
 
We describe 40 cases of EI and 16 cases of EN as controls. Cases were collected 
retrospectively at a single institution (Groote Schuur Hospital, Cape Town, South 
Africa) over a period of 14 years 2004-2018.  The cases were identified via a 
database used by the department of dermatology, containing all cases seen in their 
clinic where biopsies were performed.  These cases are all discussed at an 
interdepartmental dermatology-pathology meeting where a final diagnosis is 
reached. This study was approved by the Human Research Ethics Committee of the 
University of Cape Town.  Consent was taken from each patient before the 
commencement of the biopsy. 
 
The inclusion criteria were:  
1) Cases where a clinical-pathological diagnosis of EI or EN was made.  
2) Patients above the age of 12.   
 
The exclusion criteria were:  
1) Outstanding clinical records, images or histology reports.   
2) Cases with insufficient or poor clinical images. 
 
Clinical data collected included demographics, description of lesions and a brief 
presenting complaint with relevant clinical history.  All biopsy specimens underwent 
histopathological assessment that included hematoxylin-eosin (H&E) and various 
special stains (Ziehl–Neelsen, Brown-Brenn, Grocott-Gomori's Methenamine Silver).  
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Most cases also had specimens submitted for microbiologic examination including 
culturing methods to detect mycobacterium tuberculosis.  
 
Six qualified dermatologists with collectively 108 years of clinical experience in 
dermatology took part in the assessment.  The EI and EN cases where randomized 
and presented in a Microsoft PowerPoint presentation.  Each case had 2 
components:  
1) Relevant clinical history and images.  
2) The corresponding microscopic description in the histology report.   
 
For each case, after viewing the first component, the assessor recorded their likely 
diagnosis (EI/EN/unsure).  The second component then followed where they had 
another opportunity to record their diagnosis (EI/EN/unsure).   
 
Diagnostic accuracy was studied using confusion matrices created using the 
diagnosis based on clinical impression alone.  The results were then compared to 
the diagnostic accuracy with the additional microscopic description.  Inter-rater 
variability was assessed using Fleiss’-kappa. Demographic, clinical, laboratory data 
and assessors’ answers were stored in Microsoft Excel.  Data analysis was 
performed in R version 4.0.2 and Python version 3.7.4. 
 
Exploratory data analysis (EDA) was performed on the full dataset to determine any 
possible relationships that might aid in the successful diagnosis of EI.  Feature 
Importance analysis was performed using Scikit-learn's Random Forest algorithm to 
determine the features with the greatest predictive power.  Input features for 
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consideration were the location of the lesion, ulceration, vasculitis and septal or 
lobular panniculitis.  The best features were then selected for multivariate logistic 
regression. Incomplete data was removed from the modeling process, this removed 
seven entries from the original dataset.  The dataset was further split into a training 
and testing test.  The testing set consisted of 33% of the remaining data and was 




In this study, 56 patients with lower leg panniculitis were included, 40 (71%) EI cases 
and 16 (29%) EN cases to serve as controls.  Of the EI cases 38 (95%) were female 
with an average age of 33.3 years (+/- 11.8 years).  The EN cases consisted of 15 
(94%) female patients and an average age of 41 years (+/- 9.7 years). 
 
Clinically detectable ulceration was detected in 25 (63%) of the EI cases and 1 (6%) 
of the EN cases.  The predominant distribution of the lesions in EI was on both the 
calves and shins of the lower legs 22 (55%), followed by 11 (28%) distributed on the 
calves, 3 (8%) spread across the thighs and lower legs, 3 (8%) on the shins and 1 
(3%) widespread on the legs and arms.  The EN predominant distribution of lesions 
included both the calves and the shins 5 (31%), thighs and lower legs 4 (25%), 
predominantly shins 3 (19%), legs and arms 3 (19%) and 1 (6%) on the calves 
(Table 1). 
 
Tissue cultures aimed specifically to detect mycobacterium tuberculosis (MTB) were 
performed in 19 of the EI cases and 11 of the EN cases, all cultures were negative.  
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Special stains performed included Ziehl-Neelsen, Brown-Brenn and Grocott-
Gomori's Methenamine Silver; they were all negative. The predominant focus of 
infiltration in the panniculus (septal, lobular or septolobular) was reported in 36/40 of 
the EI cases and 16/16 of the EN cases.  The EI cases were predominantly lobular 
24/36 (67%) or septolobular 10/36 (28%), two of the cases were described as having 
a septal predominance.  Of the EN cases there was a clear predominance of a 
septal pattern 14/16 (88%), with two cases described as septolobular.  Granulomas 
were detected in 37 (95%) of the reported 39 EI cases and 10 (71%) of the reported 
14 EN cases.  Both necrotizing and non-necrotizing granulomas were described in EI 
and EN cases.  Vasculitis was present in 23/37 (62%) of the EI cases, three cases 
did not report on the presence or absence of vasculitis.  No vasculitis was detected 
in 12 of the EN specimens, four did not report on vasculitis. (Table 2). 
 
Six assessors reviewed the 56 EI and EN cases in a randomized presentation.  After 
assessing the clinical images together with the presenting complaint and relevant 
history 48.8% of the EI cases and 74% of the EN cases were correctly diagnosed.  
After each clinical image the microscopic description in the histology report was 
revealed, with this added information the assessors now correctly identified 67.1% of 
the EI cases and 81.2% of the EN cases.  At times the assessors were unsure of the 
diagnosis, this was the case in 12.1% EI and 12.5% EN clinical diagnoses and 
18.3% EI and 12.5% EN diagnoses with added microscopic findings.  Overall inter-
rater variability showed fair agreement when considering the clinical images only 
with a Fleiss’-Kappa score of 0.321 (p-value < 0.01).  Inter-rater variability was 
improved to 0.424 (p-value < 0.01) after the addition of the microscopic findings, now 
showing moderate inter-rater variability.  EI cases showed inter-rater variability of 
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0.478 (p-value < 0.01) before and 0.469 (p-value < 0.01) after histology was 
revealed. EN cases had inter-rater variability of 0.331 (p-value < 0.01) before and 
0.549 (p-value < 0.01) after histology was revealed.  (Table 3) 
 
The final logistic regression model disregarded the location of the lesion and 
included ulceration, vasculitis and lobular or septal panniculitis.  The model showed 
an in-sample accuracy of 96.6% compared to an out-of-sample accuracy of 94.1%.  
On the test set, the assessors were accurate in 79.2% and 83.3% of cases for EI 
and EN respectively.  The model was accurate in 100% and 80% of EI and EN cases 
respectively, showing an improvement in the diagnosis of EI and similar results to 




Our cohort of 40 EI patients is similar in size to the largest cohorts in the literature. A 
previous study done in South Korea identified 53 patients prospectively and in Brazil 
54 cases retrospectively. (15-16). In Spain 86 cases were collected retrospectively at 2 
institutions and 65 cases at one institution. (9, 17, 19) These make out the largest 
cohorts, few studies correlate the clinical and histological features of this condition. 
 
There was a clear predominance of female cases, this is in keeping with previous 
reported literature.  EI lesions were distributed predominantly on the anterior and 
posterior legs, contradicting the usual interpretation that EI presents on the calves 
and EN on the shins. (13). Ulceration, a helpful clinical feature, was present in only 
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62% of EI cases but notably absent in the EN cases.  Although a previous large 
cohort of 54 patients detected an ulceration rate of only 24% of EI cases. (15) 
 
Microbiological cultures and special stains for infective organisms on histology were 
all negative.  Because MTB cannot be cultured in the lesion the etiological relation to 
EI remains controversial. However, in recent years numerous studies reported the 
presence of MTB DNA by polymerase chain reaction (PCR). These results include 
positive MTB DNA detection by PCR in 77% of 65 patients, 75% of 12 patients, 14% 
of 65 patients and 25% of 20 patients with EI. (17-21)  
 
Histological features of EI were predominantly septal or septolobular.  Vasculitis was 
present in 62% of cases, previous literature reports 90%. (9) A similar study done by 
Rademaker et al, reviews clinical and histologic features of 26 cases of EI. The 
characteristic cutaneous lesions on the legs of middle-aged women were violaceous, 
indurated nodules, occasionally ulcerated, and could heal with scarring. The 
histologic features were varied but were predominantly those of a vasculitis with a 
septolobular and lobular panniculitis. (22) 
 
For the assessors, diagnostic accuracy increased from 48.8% to 67.1% for EI and 
from 74% to 81.2% for EN after the histology was revealed.  We saw a slight 
decrease in inter-rater reliability in the diagnosis of EI compared with a large 
increase in inter-rater reliability for the diagnosis of EN.  Thus, for the EI cases the 
addition of histological features did not lead to more concordance between 
assessors.  Assessors had substantial agreement on the histological features of EN. 
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Feature importance analysis showed that the location of the lesion was not as 
important as ulceration, vasculitis and septal or lobular panniculitis.  The single most 
important feature being a septal panniculitis in EN in 88% of cases. (Fig. 1) 
 
Although EI has been associated with other entities the association with tuberculosis, 
a diagnosis not to be missed, remain most important in our setting where there is a 
high incidence of tuberculosis.  While the study was limited by its retrospective 
nature and small sample size, valuable features (ulceration, vasculitis and lobular or 
septal panniculitis) were identified.  These features combined in a logistic regression 
model had a higher diagnostic accuracy than the assessors with regards to EI cases.  
A biopsy of the lower leg markedly increased the diagnostic accuracy, but did not 
lead to increased concordance between assessors, more research is needed to 
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Tables for publication 
 
Table 1. Patient demographics and lesion distribution 
 EI 
n (%) or mean and SD 
EN 
n (%) or mean and SD 
Female gender 38 (95%) 15 (94%) 
Age 33.3 +/- 11.8 41 +/- 9.7 










Calves 11 (28%) 1 (6%) 
Anterior and posterior 
lower legs 
22 (55%) 5 (31%) 
Thighs and lower legs 3 (8%) 4 (25%) 











Table 2. Histopathological and Microbiological properties 
 EI 
n (%)  
EN 
n (%)  
Positive culture (positive/total) 0/19 (0%) 0/11 (0%) 

















































SD = standard deviation; EI = Erythema induratum; EN = Erythema nodosum; GMS = Grocott-





Table 3. Assessor diagnosis from clinical presentation alone and combined 
with histology report  
Diagnosis on clinical presentation 




Diagnosed EI 48.8% (117) 13.5% (13) 
Diagnosed EN 39.2% (94) 74% (71) 
Diagnosed Unsure 12.1% (29) 12.5% (12) 
Diagnosis on clinical and histological presentation 
Diagnosed EI 67.1% (161) 6.2% (6) 
Diagnosed EN 14.6% (35) 81.2% (78) 
Diagnosed Unsure 18.3% (44) 12.5% (12) 





Figures for publication 
 
Figure 1. Percentage of EI and EN cases containing each of the features.   
 








Appendix 1 – Additional tables not for publication 
 
Table 4.  Fleiss’ Kappa inter-rater reliability scores. 
  EI EN UNSURE 
KAPPA Clinical 0.478 0.331 -0.050 
Added histology 0.469 0.549 0.143 
P VALUE Clinical <0.01 <0.01 0.147 
Added histology <0.01 <0.01 <0.01 
 






Table 5.  Multivariate logistic regression model and Assessor diagnostic 
accuracy on test data. 











Assessors 79.2% 83.3% 80.4% 
 




Interpretation of Kappa values 
	 K Interpretation 
< 0 Poor agreement 
0.01 – 0.20 Slight agreement 
0.21 – 0.40 Fair agreement 
0.41 – 0.60 Moderate agreement 
0.61 – 0.80 Substantial agreement 
0.81 – 1.00 Almost perfect agreement 
 
Referenced from: 1. Landis JR, Koch GG. The measurement of observer agreement 






Appendix 2 – Additional figures not for publication 
 
Figure 2.  Random forest feature importance. 
 
 
The feature importance of the different features can be seen in Figure 2.  The bars 
show the mean feature importance over all the trees in the random forest model.  









The test set, not used during the training process, was used to compare the out of 
sample performance of the multivariate logistic regression model with the average 
diagnosis of the assessors.  Figure 3 shows the ROC curve of the out of sample 
results with an AUC of 0.98 showing that the model performs significantly better than 
random. 
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Appendix 4 – STROBE Checklist  
STROBE Statement—Checklist of items that should be included in reports of cohort studies  
 Item 
No Recommendation                                                                 
 
Comments 
 Title and 
abstract 
1P (a) Indicate the study’s design with a commonly used term in the 
title or the abstract 
p. 28 
(b) Provide in the abstract an informative and balanced summary of 





2P  Explain the scientific background and rationale for the investigation 
being reported 
p. 29-32 
Objectives 3P State specific objectives, including any prespecified hypotheses p. 29-32 
Methods  
Study design 4P Present key elements of study design early in the paper p. 33-35 
Setting 5P Describe the setting, locations, and relevant dates, including periods 
of recruitment, exposure, follow-up, and data collection 
p. 33-35 
Participants 6P (a) Give the eligibility criteria, and the sources and methods of 
selection of participants. Describe methods of follow-up 
p. 33-35 
(b) For matched studies, give matching criteria and number of 
exposed and unexposed  
p. 33-35 
Variables 7P Clearly define all outcomes, exposures, predictors, potential 





8P  For each variable of interest, give sources of data and details of 
methods of assessment (measurement). Describe comparability of 
assessment methods if there is more than one group:  
p. 33-35 
Bias 9P Describe any efforts to address potential sources of bias: p. 33-35 
Study size 10P Explain how the study size was arrived at: Prior studies were 




11P Explain how quantitative variables were handled in the analyses. If 




12P (a) Describe all statistical methods, including those used to control 
for confounding  
p. 33-35 
(b) Describe any methods used to examine subgroups and 
interactions  
p. 33-35 
(c) Explain how missing data were addressed  p. 33-35 
(d) If applicable, explain how loss to follow-up was addressed  N/A 
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(e) Describe any sensitivity analyses  p. 33-35 
Results  
Participants 13P (a) Report numbers of individuals at each stage of study—eg 
numbers potentially eligible, examined for eligibility, confirmed 
eligible, included in the study, completing follow-up, and analysed  
p. 35-37 
(b) Give reasons for non-participation at each stage p. 35-37 
(c) Consider use of a flow diagram N/A 
Descriptive 
data 
14P (a) Give characteristics of study participants (eg demographic, 
clinical, social) and information on exposures and potential 
confounders  
p. 35-37 
(b) Indicate number of participants with missing data for each 
variable of interest  
p.35-37 
(c) Summarise follow-up time (eg, average and total amount) N/A 
Outcome data 15P Report numbers of outcome events or summary measures over time p.35-37 
Main results 16P (a) Give unadjusted estimates and, if applicable, confounder-
adjusted estimates and their precision (eg, 95% confidence interval). 
Make clear which confounders were adjusted for and why they were 
included  
N/A 
(b) Report category boundaries when continuous variables were 
categorized  
N/A 
(c) If relevant, consider translating estimates of relative risk into 




17P Report other analyses done—eg analyses of subgroups and 
interactions, and sensitivity analyses 
p.35-37 
Discussion  
Key results 18P Summarise key results with reference to study objectives p. 37 
Limitations 19P Discuss limitations of the study, taking into account sources of 
potential bias or imprecision. Discuss both direction and magnitude 




Give a cautious overall interpretation of results considering 
objectives, limitations, multiplicity of analyses, results from similar 






Discuss the generalisability (external validity) of the study results p. 39 
Other information  
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Funding 22P Give the source of funding and the role of the funders for the 
present study and, if applicable, for the original study on which the 




*Give information separately for exposed and unexposed groups. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological 
background and published examples of transparent reporting. The STROBE checklist is best used in conjunction 
with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals 
of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on 
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Author Guidelines 
IJD SUBMISSION FORMS 
Online Submission 
Contact the Editorial Office 
1. ABOUT IJD 
Published monthly, the International Journal of Dermatology (IJD) is specifically designed to 
provide dermatologists around the world with a regular, up-to-date source of information on all 
aspects of the diagnosis and management of skin diseases. Accepted articles regularly cover 
clinical trials, education, morphology, pharmacology and therapeutics, case reports, and reviews. 
Additional features include tropical medicine reports, news, correspondence, and proceedings 
and transactions. 
IJD is guided by a distinguished, international editorial board and emphasizes a global approach 
to continuing medical education for physicians and other providers of health care with a specific 
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2. MANUSCRIPT CATEGORIES 
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Case Report* 
A report of 400–600 words, illustrated by no more than three illustrations. This category offers a 
means for rapid communication about a single subject. 
Clinical Trial 
An article of 700–1200 words concerning a drug evaluation. This category provides rapid 
publications and is meant to be a succinct presentation with a minimum of graphs and tables. 
Commentary* 
An editorial 700–1200 words in length with approximately five references. The author may 
express his or her opinion without complete documentation. 
Clinicopathological Challenge* 
A photographic essay that includes both a clinical and a pathological photograph in color. The 
diagnosis and legends for the photographs should be listed after the references in the article. 
The article should be no more than 2 pages in length and contain 4-5 references. 
Correspondence* 
Letters to the editor and short notes. Contributions should not exceed 600 words, two figures, 
and 5 references. In order to offer rapid dissemination of accepted manuscripts, Correspondence 
items will be published online-only. Online-only correspondence items are assigned to an issue 
of the journal, but are excluded from the print edition. Online-only correspondence items are e-
paginated and are fully citable and indexable. 
Dermatological Surgery 
An article relating to the surgical aspects of treatment. Article types may include Review, Report 
or Correspondence format. 
Education 
An article about the methodology of curriculum and instruction in dermatology, about 2500 
words. 
On a Human Scale* (by invitation only) 
An article that relates to social, economic, cultural, artistic and humanitarian aspects of medicine. 
The length of the article should not exceed 1200 words including a short summary of the topic 
addressed. A brief author biography and photo should be submitted with the article. If you have a 
topic that you feel would fit nicely in this section, please send a note 
to IntJDerm@gmail.com for approval to submit. 
Pharmacology and Therapeutics 
An article relating to the treatment of diseases and to the pharmacology of dermatologically-
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related drugs. (Can include Clinical Trials, Reviews, Reports, and Correspondence. The latter is 
preferred for reports of adverse drug reactions.) When referring to a drug, please use the generic 
name approved by the United States Food and Drug Administration or recognized as the United 
States Adopted Name. At the end of the manuscript, please list the American Trade names. 
Reminiscence 
An article on the history of dermatology or skin diseases; also a biographic account of an historic 
or noteworthy figure in dermatology. 
Report 
An original article including, whenever possible, an Introduction, Materials and Methods or Case 
Report(s), Results, Comment, and References. A Structured Abstract of not more than 250 
words must be included and should consist of four paragraphs labeled Background, Methods, 
Results, and Conclusions. Also, it should describe the problem studied, how the study was 
performed, the main results, and what the author(s) concluded from the results. The article 
should range from 2500-3000 words. 
Review 
A major didactic article that clarifies and summarizes the existing knowledge in a particular field. 
It should not be an exhaustive review of the literature, and references should not exceed 50 in 
number. Tables, diagrams, and selected figures are often helpful and preferred. The length is left 
to the judgment of the author, although it generally should not exceed 5000 words. Topics may 
include updates in clinically relevant basic science and cutaneous biology. A list of 10 multiple 
choice and/or true and false questions should be listed at the end of the article to provide 
additional educational challenge to the reader. An abstract is required, though it need not be 
structured. 
Tropical Medicine Rounds 
An article dealing with the diseases and special problems encountered by dermatologists 
working in the tropics. Article submissions should follow the Report, Case Report, or 
Correspondence format. 
Updates in Medicine 
This contribution to the journal should be 700–1200 words in length with sufficient references to 
document important points. It is not essential that the contribution be heavily referenced as it is 
meant to serve as an update for dermatologists in various fields of medicine and is not portrayed 
to be an extensive or exhaustive review of the literature. However, it would be very helpful if 
pertinent and salient references are included, not only for documentation purposes, but also for 
additional reading. 
Medical Genetics 
Report, Review or Correspondence format should be followed. 
*No abstract required 
3. SUBMISSION OF MANUSCRIPTS 
Submissions should be made online at the IJD ScholarOne Manuscripts site (formerly known 
as Manuscript Central). New users should first create an account (do not upload document files 
at this time). Once a user is logged onto the site, submissions should be made via the Author 
Center. 
Revised manuscripts must be submitted as revisions as directed by the ScholarOne website. Do 
not resubmit a revision as a new manuscript as this may result in re-review and considerable 
delay. The revision should be complete and contain all the tables and figures. Do not resubmit 
the original manuscript with your revision. 
Submission of a manuscript will be held to imply that it contains original unpublished work and is 
not being submitted for publication elsewhere at the same time. The author must supply a full 
statement to the Editor about all submissions and previous reports that might be regarded as 
redundant or duplicate publication of the same or very similar work. 
By submitting a manuscript to, or reviewing for, this publication, your name, email address, 
institutional affiliation, and other contact details the publication might require, will be used for the 
regular operations of the publication, including, when necessary, sharing with the publisher 
(Wiley) and partners for production and publication. The publication and the publisher recognize 
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the importance of protecting the personal information collected from users in the operation of 
these services, and have practices in place to ensure that steps are taken to maintain the 
security, integrity, and privacy of the personal data collected and processed. You can learn more 
at https://authorservices.wiley.com/statements/data-protection-policy.html. 
4. PREPARATION OF MANUSCRIPTS 
Manuscripts must be written in English and must comply with these instructions in every detail. 
Text should be supplied in a word processed format such as Microsoft Word for Windows. Charts 
and tables are considered textual and should be supplied in the same format. Figures 
(illustrations, diagrams, photographs) should be supplied in gif, jpeg, tif or eps format. 
All manuscripts must be typed in 12 pt font with lines double spaced and margins of at least 2.5 
cm. 
Abbreviations must be defined when first used, both in the abstract and in the main text. 
Manuscripts must be as succinct as possible. Text must comply with the word and figure limits 
defined in Section 2. If authors consider that a manuscript should not conform to the limits 
specified, exceptionally good reasons must be clearly provided in a cover letter accompanying 
the submission. Repetition of information or data in different sections of the manuscript must be 
carefully avoided. 
Manuscripts should, where appropriate, include: 
Title Page 
The first page of all manuscripts should contain the following information: 
1) the title of the paper 
2) surnames (family names),initials of each author, and their degree (if any) 
3) name of the institution(s) at which the research was conducted 
4) name, address, telephone number and email address of corresponding author 
5) manuscript word count (excluding abstract and references), table and figure count 
7) any conflict of interest disclosures (see Section 5) 
8) a running head not exceeding 50 characters 
Abstracts 
Authors submitting Reports should note that structured abstracts (maximum 250 words) are 
required. The structured abstract should adopt the format: Background, Methods, Results, 
Conclusions. 
Review articles require abstracts (maximum 250 words) but they need not be structured. 
Abstracts should not contain citations. 
Text 
This should in general, but not necessarily, be divided into sections with the headings: Abstract, 
Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, 
Tables, Table and figure legends. Figures should be submitted as separate files. The 
acknowledgements should include a statement of all funding sources that supported the work. 
Please submit the full text of the manuscript, including the abstract, references, tables and 
legends as a single document. The title page may be included as page 1 of the main manuscript 
document or can be uploaded as a separate file, but must be included. 
Tables and Figures 
Tables should not be inserted in the appropriate place in the text but should be included at the 
end of the manuscript, each on a separate page. 
Figures (illustrations, diagrams, photographs) should be supplied in gif, jpeg, tif or eps format 
and submitted as separate electronic files. 
Tables and figures should be referred to in text as follows: Fig. 1, Figs. 2–4; Table 1, Tables 2 
and 3. The place at which a table or figure is to be inserted in the printed text should be indicated 
clearly on a manuscript. Each table and/or figure must have a legend that explains its purpose 
without reference to the text. Where a figure has more than one panel, each panel should be 
labelled in the top left-hand corner using lower case letters in parentheses i.e. ‘(a)’, ‘(b)’ etc., and 
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a brief description of each panel given in the figure legend. When using histology figures, the 
stain type and magnification level must be included in the legend. 
Only figures of excellent quality will be considered for publication. The Journal will publish color 
photographs free of charge subject to editorial approval. When an individual is identifiable in a 
photograph written permission must be obtained (see Section 5 ‘Ethics’ below). 
Authors are themselves responsible for obtaining permission to reproduce previously published 
figures or tables. 
References 
References should be in Vancouver format and appear as consecutive, unbracketed superscript 
numbers in the text, e.g. ‘in our previous reports1,2 and those of Smith et al.3–5’ and should be 
listed numerically in the reference list at the end of the article. 
Format references as below, using standard (Medline) abbreviations for journal titles. When 
there are more than four authors, include the first three authors followed by et al. 
1. de Berker DAR, Baran R, Dawber RPR. The Nail in Dermatological Diseases. In: Baran and 
Dawber's Diseases of the Nails and their Management (Baran R, Dawber RPR, de Berker DAR, 
Haneke E, Tosti, A, eds), 3rd edn. Oxford: Blackwell Science Ltd., 2001: 172–92. 
2. Murray ML, Cohen JB. Mycophenolate mofetil therapy for moderate to severe atopic 
dermatitis. Clin Exp Dermatol 2007; 32: 23–7. 
3. Graham-Brown R, Burns T. Lecture Notes: Dermatology. Oxford: Wiley-Blackwell, 2006. 
4. Smith A. (1999) Select committee report into social care in the community [WWW document]. 
URL http://www.dhss.gov.uk/reports/report015285.html [accessed on 7 November 2003]. 
5. DECLARATIONS 
Original Publication 
Submission of a manuscript will be held to imply that it contains original unpublished work and is 
not being submitted for publication elsewhere at the same time. The author must supply a full 
statement to the Editor about all submissions and previous reports that might be regarded as 
redundant or duplicate publication of the same or very similar work. 
Conflicts of Interest 
Authors are responsible for disclosing all financial and personal relationships between 
themselves and others that might be perceived by others as biasing their work. To prevent 
ambiguity, authors must state explicitly whether potential conflicts do or do not exist. 
Ethics 
When reporting experiments on human subjects, indicate whether the procedures followed were 
in accordance with the ethical standards of the responsible committee on human 
experimentation (institutional or regional) and with the Helsinki Declaration of 1975, as revised in 
1983. Do not use patients' names, initials or hospital numbers, especially in illustrative material. 
When reporting experiments on animals, indicate whether the institution's or a national research 
council's guide for, or any national law on, the care and use of laboratory animals was followed. 
A statement describing explicitly the ethical background to the studies being reported should be 
included in all manuscripts in the Materials and Methods section. Ethics committee or institutional 
review board approval should be stated. 
Patients have a right to privacy that should not be infringed without informed consent. Identifying 
information should not be published in written descriptions, photographs and pedigrees unless 
the information is essential for scientific purposes and the patient (or parent or guardian) gives 
written informed consent for publication. Identifying details should be omitted if they are not 
essential but patient data should never be altered or falsified in an attempt to attain anonymity. 
Complete anonymity is difficult to achieve and informed consent should be obtained if there is 
any doubt. For example, masking the eye region in photographs of patients is inadequate 
protection of anonymity. 
Authorship 
All persons designated as authors should qualify for authorship and all those who qualify should 
be listed. Each author should have participated sufficiently in the work to take public 
responsibility for appropriate portions of the content. One or more authors should take 
responsibility for the integrity of the work as a whole, from inception to published article. 
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Authorship credit should be based only on 1) substantial contributions to conception and design, 
or acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it 
critically for important intellectual content; 3) final approval of the version to be published. 
Conditions 1, 2 and 3 must all be met. Acquisition of funding, the collection of data or general 
supervision of the research group, by themselves, do not justify authorship. All others who 
contributed to the work who are not authors should be named in the Acknowledgements section. 
Committee on Publication Ethics (COPE) 
As a member of the Committee on Publication Ethics (COPE), adherence to these submission 
criteria is considered essential for publication in IJD; mandatory fields are included in the online 
submission process to ensure this. If, at a later stage in the submission process or even after 
publication, a manuscript or authors are found to have disregarded these criteria, it is the duty of 
the Editor to report this to COPE. COPE may recommend that action be taken, including but not 
exclusive to, informing the authors' professional regulatory body and/or institution of such a 
dereliction. 
The website for COPE may be accessed at: http://www.publicationethics.org.uk 
6. ADDITIONAL INFORMATION ON ACCEPTANCE 
Author services 
Author Services enables authors to track their article—once it has been accepted—through the 
production process to publication online and in print. Authors can check the status of their 
articles online and choose to receive automated e-mails at key stages of production. The author 
will receive an e-mail with a unique link that enables them to register and have their article 
automatically added to the system. Please ensure that a complete e-mail address is provided 
when submitting the manuscript. Visit http://authorservices.wiley.com/bauthor for more details 
on online production tracking and for a wealth of resources including FAQs and tips on article 
preparation, submission and more. 
If your paper is accepted, the author identified as the formal corresponding author for the paper 
will receive an email prompting them to login into Author Services; where via the Wiley Author 
Licensing Service (WALS) they will be able to complete the license agreement on behalf of all 
authors on the paper. 
For authors signing the copyright transfer agreement 
If the OnlineOpen option is not selected the corresponding author will be presented with the 
copyright transfer agreement (CTA) to sign. The terms and conditions of the CTA can be 
previewed in the samples associated with the Copyright FAQs below: CTA Terms and 
Conditions http://authorservices.wiley.com/bauthor/faqs_copyright.asp 
For authors choosing OnlineOpen 
If the OnlineOpen option is selected the corresponding author will have a choice of the following 
Creative Commons License Open Access Agreements (OAA): 
Creative Commons Attribution Non-Commercial License OAA 
Creative Commons Attribution Non-Commercial - NoDerivs License OAA 
To preview the terms and conditions of these open access agreements please visit the Copyright 
FAQs hosted on Wiley Author Services 
http://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit 
http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html. 
If you select the OnlineOpen option and your research is funded by The Wellcome Trust and 
members of the Research Councils UK (RCUK) you will be given the opportunity to publish your 
article under a CC-BY license supporting you in complying with Wellcome Trust and Research 
Councils UK requirements. For more information on this policy and the Journal’s compliant self-
archiving policy please visit: http://www.wiley.com/go/funderstatement. 
For RCUK and Wellcome Trust authors click on the link below to preview the terms and 
conditions of this license: 
Creative Commons Attribution License OAA 
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To preview the terms and conditions of these open access agreements please visit the Copyright 
FAQs hosted on Wiley Author Services 
http://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit 
http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html. 
Proofs 
The corresponding author will receive an email alert containing a link to a web site. Please 
answer all queries and update the text as required. 
Early View 
IJD is covered by the Publisher's Early View service. Early View articles are complete full-text 
articles published online in advance of their publication in a printed issue. Articles are therefore 
available as soon as they are ready, rather than having to wait for the next scheduled print issue. 
Early View articles are complete and final. They have been fully reviewed, revised and edited for 
publication, and the authors’ final corrections have been incorporated. Because they are in final 
form, no changes can be made after online publication. The nature of Early View articles means 
that they do not yet have volume, issue or page numbers, so Early View articles cannot be cited 
in the traditional way. They are therefore given a Digital Object Identifier (DOI), which allows the 
article to be cited and tracked before it is allocated to an issue. After print publication, the DOI 
remains valid and can continue to be used to cite and access the article. More information about 
DOIs can be found online at http://www.doi.org/faq.html. 
Offprints 
Free access to the final PDF offprint of your article will be available via Author Services only. 
Should you wish to purchase additional copies of your article, please click on the link and follow 
the instructions provided: 
www.sheridan.com/wiley/eoc 
Note to NIH Grantees 
Pursuant to NIH mandate, Wiley-Blackwell will post the accepted version of contributions 
authored by NIH grant-holders to PubMed Central upon acceptance. This accepted version will 
be made publicly available 12 months after publication. For further information, 
see http://www.wiley.com/go/nihmandate. 
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